Atypical neuroleptic malignant syndrome with long-term clozapine.
Clozapine-induced neuroleptic malignant syndrome (NMS) may present differently from NMS associated with traditional antipsychotic agents, with fewer clinical features, particularly fewer extrapyramidal manifestations. The risk of developing NMS with clozapine does not appear dose-related. In half of cases, it occurs within 2 weeks of beginning clozapine therapy, but it can develop at any stage, especially with long-term use. We describe a patient who presented with atypical NMS after more than 10 years of clozapine treatment, and who was safely re-challenged with the same drug.
Corallo
Carmela E
CE
Pharmacy Department, Box Hill Hospital, Box Hill, VIC.
Ernest
David
D
D014150:Antipsychotic Agents / Q000009:adverse effects*; D003024:Clozapine / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000097:blood / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D013997:Time Factors
D014150:Antipsychotic Agents; D003404:Creatinine; D003024:Clozapine